Generic Drug Makers Find Support in US Supreme Court Ruling

by Thilaka Ravi on  April 18, 2012 at 1:24 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Generic drug makers can challenge big-name pharmaceutical firms in court to stop them from broadening the scope of their patent descriptions, the US Supreme Court ruled.
Generic Drug Makers Find Support in US Supreme Court Ruling
Generic Drug Makers Find Support in US Supreme Court Ruling

The measure overturns a 2010 appeals court ruling and confirms an earlier decision by a federal judge that ordered the US subsidiary of Danish laboratory Novo Nordisk to narrow the description of its patent on repaglinide, an anti-diabetes drug sold under the name Prandin.

Caraco Pharmaceutical Laboratories, the US subsidiary of the Indian firm Sun Pharmaceutical Industries, is seeking to produce a generic version of Prandin.

However Novo Nordisk amended the wording of his patent to extend it, and block the Caraco's request to the US Food and Drug Administration (FDA) to produce a generic version of the drug.

The FDA cannot approve the sale of a drug that breaks patent protection laws.

In a unanimous decision by the nine Supreme Court justices on Tuesday, Justice Elena Kagan wrote that "a generic company can employ the counterclaim to challenge a brand's overbrand use code."

"We accordingly hold that Caraco may bring a counterclaim seeking to 'correct' Novo's use code," the ruling read.

"While we are disappointed with the decision," said James Shehan, a senior official with Novo Nordisk Inc, USA, "it appears the Supreme Court has held only that Caraco may challenge the use code narrative for Novo Nordisk's patented method of treating diabetes with repaglinide in combination with metformin.

"Novo Nordisk's use code narrative is, and has always been, correct, and we are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," Shehan said.

In 2011, US sales of Novo Nordisk drugs Prandin and PrandiMet totaled $175.96 million (about one billion Danish kroner), according to the firm.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive